Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ALLO

ALLO - Allogene Therapeutics Inc Stock Price, Fair Value and News

3.05USD-0.37 (-10.82%)Market Closed

Market Summary

ALLO
USD3.05-0.37
Market Closed
-10.82%

ALLO Stock Price

View Fullscreen

ALLO RSI Chart

ALLO Valuation

Market Cap

521.1M

Price/Earnings (Trailing)

-1.78

Price/Sales (Trailing)

6.0K

EV/EBITDA

-1.79

Price/Free Cashflow

-2.29

ALLO Price/Sales (Trailing)

ALLO Profitability

EBT Margin

-295408.05%

Return on Equity

-63.35%

Return on Assets

-49.85%

Free Cashflow Yield

-43.65%

ALLO Fundamentals

ALLO Revenue

Revenue (TTM)

87.0K

Rev. Growth (Yr)

-26.67%

Rev. Growth (Qtr)

4.76%

ALLO Earnings

Earnings (TTM)

-292.3M

Earnings Growth (Yr)

34.98%

Earnings Growth (Qtr)

24.22%

Breaking Down ALLO Revenue

Last 7 days

13.8%

Last 30 days

36.8%

Last 90 days

-12.1%

Trailing 12 Months

-43.6%

How does ALLO drawdown profile look like?

ALLO Financial Health

Current Ratio

12.8

ALLO Investor Care

Shares Dilution (1Y)

17.15%

Diluted EPS (TTM)

-1.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202487.0K000
2023147.0K105.0K100.0K95.0K
202285.6M57.1M28.6M156.0K
2021000114.1M

Tracking the Latest Insider Buys and Sells of Allogene Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 18, 2024
messemer deborah m.
sold
-42,488
2.2793
-18,641
-
Jun 05, 2024
sato vicki l
acquired
-
-
61,475
-
Jun 05, 2024
humer franz b
acquired
-
-
61,475
-
Jun 05, 2024
messemer deborah m.
acquired
-
-
122,950
-
May 30, 2024
humer franz b
sold
-26,181
2.3376
-11,200
-
May 16, 2024
chang david d
acquired
1,000,000
2.9
344,828
president and ceo
May 16, 2024
belldegrun arie
bought
5,000,000
2.9
1,724,140
-
May 16, 2024
parker geoffrey m.
acquired
1,000,000
2.9
344,828
chief financial officer
May 16, 2024
belldegrun arie
acquired
1,000,000
2.9
344,828
-

1–10 of 50

Which funds bought or sold ALLO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 17, 2024
Phoenix Wealth Advisors
new
-
30,290
30,290
0.01%
Jul 16, 2024
AdvisorNet Financial, Inc
reduced
-9.09
-517
466
-%
Jul 16, 2024
SHIKIAR ASSET MANAGEMENT INC
unchanged
-
-33,000
37,000
0.01%
Jul 12, 2024
SG Americas Securities, LLC
reduced
-62.13
-126,000
31,000
-%
Jul 11, 2024
BOURGEON CAPITAL MANAGEMENT LLC
added
131
52,937
308,621
0.06%
Jul 10, 2024
NBC SECURITIES, INC.
sold off
-100
-1,000
-
-%
Jul 10, 2024
CWM, LLC
new
-
-
-
-%
Jul 10, 2024
Vida Ventures Advisors, LLC
unchanged
-
-3,848,070
4,189,720
4.58%
Jul 09, 2024
HARBOR CAPITAL ADVISORS, INC.
sold off
-100
-433,000
-
-%
Jul 09, 2024
LAZARD ASSET MANAGEMENT LLC
reduced
-35.63
-2,000
16,000
-%

1–10 of 47

Are Funds Buying or Selling ALLO?

Are funds buying ALLO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALLO
No. of Funds

Unveiling Allogene Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
chang david d
5.8%
9,964,347
SC 13G/A
Feb 14, 2024
belldegrun arie
5.8%
9,895,903
SC 13G/A
Feb 13, 2024
vanguard group inc
5.37%
9,030,825
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 29, 2024
blackrock inc.
5.9%
10,001,804
SC 13G/A
Jan 23, 2024
state street corp
1.44%
2,427,284
SC 13G/A
Oct 25, 2023
pfizer inc
13.14%
22,032,040
SC 13D/A
Jul 10, 2023
fmr llc
-
0
SC 13G
Feb 13, 2023
chang david d
5.7%
8,427,632
SC 13G
Feb 13, 2023
belldegrun arie
6.1%
8,858,861
SC 13G/A

Recent SEC filings of Allogene Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 20, 2024
4
Insider Trading
Jun 18, 2024
144
Notice of Insider Sale Intent
Jun 11, 2024
3
Insider Trading
Jun 10, 2024
8-K
Current Report
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading

Peers (Alternatives to Allogene Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.5B
6.8B
-8.98% -3.09%
-7.79
6.94
-64.45% -224.75%
29.9B
2.0B
53.85% 15.29%
-90.17
14.95
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
15.8B
2.5B
-0.97% -4.31%
77.01
6.4
13.74% 186.89%
14.7B
3.8B
6.43% 3.96%
19.7
3.9
8.58% 129.81%
MID-CAP
4.9B
107.9M
-6.08% -24.75%
-8.88
48.09
54.84% -28.31%
4.6B
524.1M
-5.24% -6.22%
-11.04
8.79
394.93% 39.61%
3.9B
251.0M
7.93% 10.52%
-13.15
15.52
73.58% -86.73%
3.4B
240.7M
17.18% -20.08%
-7.25
12.77
-1.03% -213.92%
3.0B
813.8M
21.05% -43.59%
-1.7K
3.65
56.43% 98.83%
2.1B
996.6M
8.34% 84.22%
-5.26
2.1
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
11.69% 23.21%
30.33
4.8
60.38% -34.49%
565.8M
881.7K
20.84% 614.44%
-16.76
481.06
-77.61% 33.36%
269.0M
4.2M
21.26% 49.14%
-2.15
64.66
-66.30% 48.24%
18.2M
2.1M
-7.46% -80.82%
-0.79
7.61
-13.45% 69.54%

Allogene Therapeutics Inc News

Latest updates
MarketBeat10 hours ago
American Banking and Market News12 hours ago
Investing.com20 May 202407:00 am

Allogene Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Revenue4.8%22.0021.0022.0022.0030.0026.0027.0064.0037,85875,65149.0044.0038,345
Operating Expenses-18.3%69,52685,13063,01880,56299,12296,42182,53876,68080,05373,94477,71971,07371,546
  S&GA Expenses0.2%17,26717,22417,04118,52418,88421,00218,89719,50919,89719,96118,99918,78316,363
  R&D Expenses-4.4%52,25954,66145,97762,03880,23875,41963,64157,17160,15653,98358,72052,29055,183
EBITDA Margin-9.2%-2.79-2.56-2.43-2.31-1.65-1.56-8.43*-4.26*-2.86*-2.16*---
EBT Margin-9.2%-2.95-2.71-2.57-2.45-1.75-1.65-8.97*-4.50*-3.00*-2.25*---
Net Income24.2%-65,000-85,778-62,287-79,232-99,968-97,275-84,242-80,290-78,60786.00-78,186-70,936-33,015
Net Income Margin2.5%-3.36-3.44-3.39-3.44-2.46-2.18-8.49*-4.15*-2.66*-1.60*---
Free Cashflow-3.7%-55,907-53,888-55,542-62,145-67,674-63,788-47,878-43,905-70,139-46,172-52,225-52,072-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-8.8%5866437137737508228949569781,0511,0791,1271,1791,2281,2231,259689718696734749
  Current Assets-13.9%395459473502481529569513470471503602716845854910504545510512477
    Cash Equivalents-38.6%51.0083.0069.0015512072.0074.0096.0085.0018419923324619316828514017916511797.00
  Net PPE-3.6%96.0099.0010310611011311411712012312612512311910385.0066.0056.0046.0036.0020.00
Liabilities-4.3%12513113315215815515114911312610910310914810495.0082.0089.0076.0078.0068.00
  Current Liabilities-16.7%31.0037.0037.0055.0059.0054.0048.0044.0037.0048.0053.0046.0055.0094.0050.0041.0027.0033.0033.0038.0027.00
Shareholder's Equity-9.9%4615125816215926677438068659259701,0241,0701,0131,1191,163607629620656681
  Retained Earnings-4.2%-1,627-1,562-1,476-1,414-1,334-1,234-1,137-1,053-973-894-828-750-679-712-577-511-450-396-335-284-243
  Additional Paid-In Capital0.7%2,0892,0752,0592,0391,9331,9121,8941,8711,8481,8221,7991,7741,7491,7261,6951,6731,0551,024953938923
Shares Outstanding1.1%170169168167145144144144144143135134---------
Float----557---1,009---2,254---3,509---1,601-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-4.1%-55,899-53,707-55,530-61,857-66,639-62,096-47,655-42,531-68,237-45,436-48,878-41,170-49,328-9,975-37,588-26,721-40,809-50,267-31,935-24,892-30,256
  Share Based Compensation-21.7%11,92415,23315,35416,59418,77017,24621,14822,89122,31522,03620,85621,13416,79216,45317,82316,77014,21513,87412,83511,4877,867
Cashflow From Investing-67.2%22,13367,461-34,26717,160112,93549,59724,90554,034-22,37729,25013,01324,59496,79822,210-83,355-428,971-15,0077,92978,77544,49232,888
Cashflow From Financing964.5%1,6501554,28589,5241,73146.001,06624.001,8143222,3833,2146,04412,9783,852600,17516,58656,4741,566236684
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ALLO Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues  
Collaboration revenue - related party$ 22$ 30
Operating expenses:  
Research and development52,25980,238
General and administrative17,26718,884
Total operating expenses69,52699,122
Loss from operations(69,504)(99,092)
Other income (expense), net:  
Interest and other income, net5,4332,059
Other expenses(929)(2,935)
Total other income (expense), net4,504(876)
Net loss(65,000)(99,968)
Other comprehensive loss:  
Net unrealized gain on available-for-sale investments283,992
Net comprehensive loss$ (64,972)$ (95,976)
Net loss per share, basic (in dollars per share)$ (0.38)$ (0.69)
Net loss per share, diluted (in dollars per share)$ (0.38)$ (0.69)
Weighted-average number of shares used in computing net loss per share, basic (in shares)169,128,362144,563,829
Weighted-average number of shares used in computing net loss per share, diluted (in shares)169,128,362144,563,829

ALLO Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 51,039$ 83,155
Short-term investments333,821365,542
Prepaid expenses and other current assets10,50410,418
Total current assets395,364459,115
Long-term investments12,4050
Operating lease right-of-use asset64,48363,703
Property and equipment, net95,93199,478
Restricted cash10,29210,292
Other long-term assets5,1596,604
Equity method investments2,7163,645
Total assets586,350642,837
Current liabilities:  
Accounts payable5,7795,897
Accrued and other current liabilities25,02931,096
Deferred revenue8686
Total current liabilities30,89437,079
Lease liability, noncurrent88,91688,346
Other long-term liabilities5,1735,179
Total liabilities124,983130,604
Commitments and Contingencies (Notes 6 and 7)
Stockholders’ equity:  
Preferred stock, $0.001 par value: 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares were issued and outstanding as of March 31, 2024 and December 31, 202300
Common stock, $0.001 par value: 400,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 170,452,967 and 168,642,238 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively170169
Additional paid-in capital2,089,3572,075,252
Accumulated deficit(1,627,233)(1,562,233)
Accumulated other comprehensive loss(927)(955)
Total stockholders’ equity461,367512,233
Total liabilities and stockholders’ equity$ 586,350$ 642,837
ALLO
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEallogene.com
 INDUSTRYBiotechnology
 EMPLOYEES359

Allogene Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Allogene Therapeutics Inc? What does ALLO stand for in stocks?

ALLO is the stock ticker symbol of Allogene Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Allogene Therapeutics Inc (ALLO)?

As of Thu Jul 18 2024, market cap of Allogene Therapeutics Inc is 521.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALLO stock?

You can check ALLO's fair value in chart for subscribers.

What is the fair value of ALLO stock?

You can check ALLO's fair value in chart for subscribers. The fair value of Allogene Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Allogene Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALLO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Allogene Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ALLO is over valued or under valued. Whether Allogene Therapeutics Inc is cheap or expensive depends on the assumptions which impact Allogene Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALLO.

What is Allogene Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 18 2024, ALLO's PE ratio (Price to Earnings) is -1.78 and Price to Sales (PS) ratio is 5.99 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALLO PE ratio will change depending on the future growth rate expectations of investors.